532321 Stock Overview
Engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Zydus Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹948.70 |
| 52 Week High | ₹1,323.90 |
| 52 Week Low | ₹628.05 |
| Beta | 0.43 |
| 11 Month Change | -5.18% |
| 3 Month Change | -19.51% |
| 1 Year Change | 48.27% |
| 33 Year Change | 100.57% |
| 5 Year Change | 272.92% |
| Change since IPO | 14,646.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532321 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.0% | 0.5% | 0.5% |
| 1Y | 48.3% | 42.5% | 27.5% |
Return vs Industry: 532321 exceeded the Indian Pharmaceuticals industry which returned 41.6% over the past year.
Return vs Market: 532321 exceeded the Indian Market which returned 25.5% over the past year.
Price Volatility
| 532321 volatility | |
|---|---|
| 532321 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 532321 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532321's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 26,921 | Sharvil Patel | zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.
Zydus Lifesciences Limited Fundamentals Summary
| 532321 fundamental statistics | |
|---|---|
| Market cap | ₹954.97b |
| Earnings (TTM) | ₹42.78b |
| Revenue (TTM) | ₹214.84b |
22.3x
P/E Ratio4.4x
P/S RatioIs 532321 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532321 income statement (TTM) | |
|---|---|
| Revenue | ₹214.84b |
| Cost of Revenue | ₹63.03b |
| Gross Profit | ₹151.81b |
| Other Expenses | ₹109.03b |
| Earnings | ₹42.78b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 42.51 |
| Gross Margin | 70.66% |
| Net Profit Margin | 19.91% |
| Debt/Equity Ratio | 0.6% |
How did 532321 perform over the long term?
See historical performance and comparison